The Next Phase Of The Obesity Drug Race
The obesity drug market is rapidly evolving beyond Wegovy and Zepbound, with new pills, triple-agonist drugs, and alternative mechanisms entering clinical pipelines. Lilly's experimental Retatrutide showed unprecedented 28% average body weight loss, the highest ever recorded for a drug. Competition is intensifying across weight loss, tolerability, and dosing convenience dimensions.
Summary
The video report covers the current state and near-future pipeline of obesity medications, filmed at the American Diabetes Association's premier obesity conference. Five years after the FDA approved Novo Nordisk's GLP-1 shot Wegovy, both Novo and Eli Lilly have begun rolling out oral pill versions of their treatments, signaling a new competitive phase in the obesity drug race.
Structure Therapeutics shared Phase 2 data showing its small-molecule GLP-1 pill achieved roughly 16% body weight loss — comparable to Lilly's pill — with the added advantage of being easier to manufacture and take. CEO Ray Stevens expressed confidence that patient-driven competition will sustain market room for new entrants, positioning Structure to capture second place behind Lilly's Orforglipron.
The headline data of the conference came from Lilly's experimental triple-agonist drug Retatrutide, which targets three hormone receptors: GLP-1, GIP, and glucagon. At the highest dose, participants lost an average of 28% of body weight, with nearly half losing more than 30% — a threshold associated with bariatric surgery outcomes. Lilly acknowledged this drug would likely target patients with BMI over 40 rather than serve as a broad-market replacement for Zepbound.
Novo's CEO Mike Doustdar reframed the long-term vision for obesity treatment, arguing that obesity will become as differentiated as mental health treatment — encompassing many distinct conditions with tailored medications within the broader cardiometabolic space. Meanwhile, Zealand Pharma and Roche are pursuing a different angle with Petrelintide, an amylin analog that achieved 11% weight loss but with significantly better tolerability, particularly around vomiting. Zealand's CEO believes its superior side-effect profile could trigger an 'iPhone moment' in the market.
Finally, Pfizer and Amgen are competing on dosing convenience. Amgen is testing monthly and quarterly dosing of its experimental drug Maritide, arguing that less frequent injections could reduce patient dropout by lowering the burden of weekly or daily medication schedules. With dozens of drugs potentially launching by 2029, the obesity treatment landscape is set for significant diversification across efficacy, tolerability, and convenience.
Key Insights
- Lilly's experimental Retatrutide produced an average 28% body weight loss at the highest dose, with nearly half of participants losing more than 30% — a level associated with bariatric surgery — making it the most weight loss ever recorded from a drug to date.
- Novo CEO Mike Doustdar argued that obesity will not remain a single monolithic condition but will become as differentiated as mental health treatment, with distinct medications for distinct conditions under the broader cardiometabolic umbrella.
- Structure Therapeutics CEO Ray Stevens said the company is specifically targeting the second market position behind Lilly's Orforglipron, betting that competition among pills ultimately benefits patients and sustains room for new entrants.
- Zealand Pharma's CEO claimed that Petrelintide's superior tolerability — especially reduced vomiting compared to GLP-1 drugs — could trigger an 'iPhone moment,' causing patients to actively queue for the new modality rather than stay on existing treatments.
- Amgen argued that monthly or quarterly dosing of its experimental drug Maritide could meaningfully reduce patient dropout, framing weekly injections and even daily pills as burdensome reminders of disease that disadvantage competing drugs.
Topics
Transcript
[0:00] It's been five years since the FDA approved Novo Nordisk GLP one shot with Govee for weight loss, and that shot in a similar one from Eli Lilly called Zepbound, have transformed the treatment of obesity, helping people lose a significant amount of weight. The drugs are also used now to treat other conditions like sleep apnea and heart problems. Behind these shots, Lilly and Novo have just started rolling out pills, and there are dozens more drugs behind them, including the most powerful drug we've seen yet, Lilly's Retatrutide. I went to the premier obesity meeting the American [0:30] Diabetes Association's to get a look at what else is inside the pipeline. Novo and Lilly introduced GLP one…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
How Retail Investors Are Using AI To Make Trades
The transcript explores the evolution of AI in retail investing, moving from AI-powered research tools to autonomous agents that can execute trades on behalf of investors. While some retail investors are building custom AI agents using tools like Claude, current implementations maintain human oversight through approval workflows, with companies cautiously implementing guardrails before AI can act independently on real money.
Why Europe is betting big on drones
Europe is dramatically increasing investment in military drone technology and AI-powered autonomous systems, driven by lessons learned from the Ukraine war. Recent developments include NATO's drone initiative, UK funding pledges, German orders for Ukraine, and major defense tech valuations, signaling that drones and their supporting technologies are now central to modern military strategy.
This new Medicare program offers obesity drugs for $50 a month. Here's what you need to know
Medicare has launched a new pilot program called Bridge that allows eligible seniors to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month copays, starting this week. This represents a major policy shift as Medicare has historically excluded obesity medications from coverage, and could potentially reach millions of beneficiaries and expand access to drugs that normally cost hundreds of dollars monthly.
Inside the rise and fall of Kohl's
Kohl's, once a beloved department store chain, experienced a dramatic decline from its 2018 peak of $82 per share to under $20, losing 70% of its value over five years. New CEO Michael Bender attributes the decline to the company losing its identity and core customer focus, and is now implementing a turnaround strategy centered on returning to the company's original value-oriented approach.
How an ICE contract could boost a stock Trump purchased
President Trump purchased up to $5 million in shares of Axon Enterprise, a Taser manufacturer, in early 2026. Exactly two weeks later, ICE announced a $220 million contract request to quadruple its Taser inventory, prompting questions about potential conflicts of interest, though the White House maintains Trump's trades are managed independently and no contract has yet been awarded.